Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00609154 · ClinicalTrials.gov registry record · Phase 1
Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates
A Phase 1 study, sponsored by Albert Einstein College of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00609154 is a Phase 1 study that was terminated before completion, run by Albert Einstein College of Medicine. The registered enrollment target is 20 participants.
The verdict
NCT00609154, a Phase 1 study, was terminated before completion, sponsored by Albert Einstein College of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The gut hormone glucagon like peptide-1 (GLP-1) has been shown to have important effects on maintaining the function and health of the insulin producing beta cells. This hormone is known to increase the production rate of new insulin as well as increase the release of insulin into the blood.
Interventions
- DRUG glucagon like peptide-1
- DIETARY_SUPPLEMENT glucose control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-08-12 |
| Est. Completion | 2014-05-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00609154
The ClinicalTrials.gov registry entry for NCT00609154 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which glucagon like peptide-1 is the first listed.
NCT00609154 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00609154 about?
NCT00609154 is a clinical study titled "Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates". The gut hormone glucagon like peptide-1 (GLP-1) has been shown to have important effects on maintaining the function and health of the insulin producing beta cells. This hormone is known to increase the production rate of new insulin as well as increase the release of insulin into the blood.
What is the current status of trial NCT00609154?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2010-08-12. Estimated completion is 2014-05-13.
What interventions are being tested in trial NCT00609154?
The interventions under investigation include: glucagon like peptide-1 (DRUG), glucose control (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00609154?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.